Evidence map›Paper›PMID 31104217›Full record

Trial reportClinical rheumatology2019

Diacerein for the treatment of rheumatoid arthritis in patients with inadequate response to methotrexate: a pilot randomized, double-blind, placebo-controlled add-on trial.

Worawit Louthrenoo, Surasak Nilganuwong, Ratanavadee Nanagara, Boonjing Siripaitoon, Sabine Collaud Basset

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01264211 (A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01264211 phase2completednot on this map

A 6-month Pilot Randomised Double-blind Placebo-controlled Multicentre, Phase 2 Study

TypeinterventionalSponsorTRB ChemedicaRan2010 to 2014Enrolled40ConditionsRheumatoid ArthritisArmsDiacerein, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Worawit LouthrenooDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. worawit.louthrenoo@cmu.ac.th.ORCID http://orcid.org/0000-0003-3105-6122
Surasak NilganuwongDivision of Rheumatology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Ratanavadee NanagaraDivision of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
Boonjing SiripaitoonDivision of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand.
Sabine Collaud BassetTRB Chemedica International SA, Geneva, Switzerland.
Chiang Mai University · THKhon Kaen University · THPrince of Songkla University · THSiriraj Hospital · THTRB Chemedica International (Switzerland) · CH

Funding

TRB Chemedica (Thailand) Ltd. DAR-THA-05-01
6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of diacerein in patients with rheumatoid arthritis (RA) who are methotrexate inadequate responders (MTX-IR).

methodIn this pilot, multicenter, double-blind, placebo-controlled trial, MTX-IR RA patients were randomized to either diacerein or matching placebo as add-on treatment to MTX for 24 weeks. Efficacy and safety were evaluated every 4 weeks until week 28. Primary and secondary efficacy endpoints were the percentage of patients achieving the ACR20 criteria and a moderate EULAR response at week 24, respectively.

resultsForty patients were equally randomized to both study treatments; 16 and 19 participants completed the study in the diacerein and the placebo arms, respectively. Baseline characteristics were similar in both groups, except that tender joint count, DAS28-ESR score, and non-steroidal anti-inflammatory drug consumption were higher in the placebo arm. The ACR20 response at week 24 was similar in the diacerein and placebo groups (65% vs 45%, P = .20). However, treatment response according to the EULAR criteria was better in patients taking diacerein (75% vs 25% of moderate response, P = .002). In the 35 patients with assessments through week 28, diacerein was superior to placebo in ACR20 at weeks 24 and 28 (both 81% vs 47%, P = .04). Incidence of adverse events was comparable in both arms, with only chromaturia being more common with diacerein than placebo (40% vs 10%, P = .03).

conclusionsThese preliminary results show the potential benefits of diacerein on pain, joint function, and disease activity in MTX-IR RA patients.

trial registrationClinicalTrials.gov Identifier: NCT01264211 Key Points • Diacerein has shown positive effects on rheumatoid arthritis symptoms. • A good safety profile of diacerein has been observed when it was administered as add-on therapy to methotrexate in patients with rheumatoid arthritis.

Indexed as

AdultAnthraquinonesAntirheumatic AgentsArthritis, RheumatoidDouble-Blind MethodFemaleHumansMaleMethotrexateMiddle AgedPilot ProjectsRetreatmentTreatment OutcomeAnthraquinonesAntirheumatic AgentsdiacereinMethotrexateDiacereinDisease activityMethotrexateRandomized controlled trialRheumatoid arthritis

Identifiers

PMID31104217
OpenAlexW2944877913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.